You are here
CENTROSE LLC
https://www.centrosepharma.com
UEI: K12MD41BMFY6
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment
Amount: $224,734.00Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cas ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
SBIR Phase I: Development of a High Throughput Glycosyl-Scanning Platform
Amount: $150,000.00This Small Business Innovation Research Phase I project highlights a strategy for the development of the first integrated high throughput pipeline to synthesize and evaluate novel sugar-drug conjugate ...
SBIRPhase I2011National Science Foundation -
A new paradigm for antibody-directed conjugates
Amount: $199,122.00DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest imp ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Amphotericin B Analogs
Amount: $277,253.00DESCRIPTION (provided by applicant): Current antifungal therapy is limited by the types of drugs available to treat systemic infections due to emerging and comparatively rare fungi different from the ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
STTR Phase I: Development of Bacterial Glycorandomization Hosts
Amount: $75,000.00This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar att ...
STTRPhase I2008National Science Foundation -
Automation of Neoglycoside Synthesis
Amount: $198,836.00DESCRIPTION (provided by applicant): The process of small molecule and natural product glycorandomization developed by Thorson and coworkers has been validated as one of the first simple, efficient an ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
novel macrolides as anti-infective drugs
Amount: $244,089.00DESCRIPTION (provided by applicant): Although it has long been known that macrolide glycosylation is absolutely essential for antibacterial activity, the megalomicins (which differ from erythromycins ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
cardiac neoglycosides as cancer drugs
Amount: $163,192.00DESCRIPTION (provided by applicant): Epidemiological evidence points to the value of cardiac glycosides like digoxin and digitoxin for treatment of breast cancer and recent reports suggest they may be ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health